EQL Pharma AB Income Statement

Financials in millions SEK. Fiscal year is April - March.

Millions SEK. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Operating Revenue	399.07	373.52	264.17	259.91	409.75	179.14
Revenue	399.07	373.52	264.17	259.91	409.75	179.14
Revenue Growth (YoY)	26.14%	41.39%	1.64%	-36.57%	128.73%	148.70%
Cost of Revenue	236.26	217.56	149.12	144.06	314.02	128.14
Gross Profit	162.81	155.95	115.05	115.85	95.73	51.01
Selling, General & Admin	89.86	78.46	70.8	59.79	48.16	28.3
Research & Development	12.45	11.26	12.09	15.14	9.13	11.7
Other Operating Expenses	-1.36	-1.14	-0.46	-0.41	-0.4	-0.51
Operating Expenses	100.95	88.58	82.43	74.51	56.9	39.48
Operating Income	61.86	67.37	32.62	41.34	38.84	11.52
Interest Expense	-23.85	-12.34	-5.73	-2.37	-2.87	-1.1
Interest & Investment Income	0.01	0.01	0.2	0	-	-
Other Non Operating Income (Expenses)	-0.68	-0.68	-0	-	0	-
EBT Excluding Unusual Items	37.34	54.36	27.08	38.97	35.97	10.42
Gain (Loss) on Sale of Investments	-	-	1.53	-	-	-
Pretax Income	37.34	54.36	28.6	38.97	35.97	10.42
Income Tax Expense	7.73	11.23	5.9	8.05	4.42	0.06
Net Income	29.61	43.12	22.71	30.92	31.55	10.37
Net Income to Common	29.61	43.12	22.71	30.92	31.55	10.37
Net Income Growth	-5.01%	89.93%	-26.57%	-1.99%	204.32%	282.97%
Shares Outstanding (Basic)	29	29	29	29	29	29
Shares Outstanding (Diluted)	30	30	30	30	29	29
Shares Change (YoY)	3.09%	0.34%	0.91%	1.59%	-	-3.37%
EPS (Basic)	1.01	1.48	0.78	1.06	1.09	0.36
EPS (Diluted)	0.98	1.44	0.76	1.04	1.09	0.36
EPS Growth	-7.66%	89.47%	-26.92%	-4.19%	204.32%	296.33%
Free Cash Flow	-19.19	-30.78	-12.36	27.16	41.2	59.64
Free Cash Flow Per Share	-0.63	-1.03	-0.41	0.92	1.42	2.05
Gross Margin	40.80%	41.75%	43.55%	44.57%	23.36%	28.47%
Operating Margin	15.50%	18.04%	12.35%	15.90%	9.48%	6.43%
Profit Margin	7.42%	11.54%	8.60%	11.90%	7.70%	5.79%
Free Cash Flow Margin	-4.81%	-8.24%	-4.68%	10.45%	10.05%	33.29%
EBITDA	71.23	75.68	38.81	47.37	40.54	16.57
EBITDA Margin	17.85%	20.26%	14.69%	18.23%	9.89%	9.25%
D&A For EBITDA	9.37	8.31	6.19	6.03	1.7	5.05
EBIT	61.86	67.37	32.62	41.34	38.84	11.52
EBIT Margin	15.50%	18.04%	12.35%	15.90%	9.48%	6.43%
Effective Tax Rate	20.70%	20.66%	20.62%	20.65%	12.28%	0.53%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.